Share

    


In This Section

Home / Advocate / Letters and Statements

Letters and Statements

ACCC writes and signs on to letters to Congress and the Administration to promote our policy interests. We also write advocacy statements, blog posts, and opinion pieces on a wide range of topics in cancer care. Questions related to health policy? Contact Matt Devino, MPH, Director, Cancer Care Delivery and Health Policy.

Follow ACCC (@ACCCBuzz) and Matt Devino (@matt_devino) on Twitter for late-breaking cancer policy news and announcements.

Latest Letters

  • ACCC Joins Radiation Oncology Community in Letter to Congress
    November 21, 2022

    In a letter to congressional leadership, ACCC joined the American Society for Radiation Oncology (ASTRO) and more than 20 other organizations asking Congress to pass legislation before the end of the year to prevent significant Medicare payment cuts to radiation therapy services. These cuts largely stem from the 2023 Medicare Physician Fee Schedule, PAYGO sequester, and clinical labor price updates.
    Read the Letter

  • ACCC Sends End-of-Year Legislative Priorities to Congressional Leadership
    October 18, 2022

    ACCC sent a letter to House and Senate leaders this week, encouraging Congress to take action before the end of this year to mitigate significant Medicare payment cuts and improve patient access to high quality, efficient, and equitable cancer care. Without congressional intervention, significant reductions to Medicare payment will take effect in January 2023, including the proposed 4.42% reduction to the Medicare Physician Fee Schedule conversion factor and 4% Statutory Pay-As-You-Go sequester. Additional priorities include supporting the transition to value-based care, extending telehealth flexibilities beyond the COVID-19 public health emergency, and improving prior authorization processes in the Medicare Advantage program.
    Read the Letter

  • ACCC Expresses Concern to FDA Regarding Inspection Delays
    October 11, 2022

    In a letter to U.S. Food and Drug Administration (FDA) Commissioner Robert Califf, M.D., ACCC raises concern about recent delays in inspections of manufacturing facility that have led to interruptions in the approval of breakthrough therapies. We are particularly concerned when these delays impact novel treatments for diseases without FDA-approved therapies available and those that disproportionately impact minority communities.
    Read the Letter

  • ACCC Encourages Congress to Extend Advanced APM Incentive Payments
    September 28, 2022

    In a letter to congressional leadership, ACCC joined 16 other healthcare associations and coalitions urging Congress to extend Medicare's 5 percent advanced alternative payment model (APM) incentive payments in an end-of-year legislative package. Originally authorized under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), these incentive payments were intended to support providers in making the transition to value-based care delivery and participating in these models through CY 2022, recognizing the significant upfront and ongoing investment necessary for participation. Absent congressional action, providers participating in advanced APMs, including the Enhancing Oncology Model, will not be eligible to qualify for these payments in CY 2023 and beyond.
    Read the Letter

  • ACCC Urges Senate Leadership to Extend Telehealth Beyond COVID-19
    September 13, 2022

    In July 2022, the House of Representatives overwhelmingly passed the Advancing Telehealth Beyond COVID-19 Act (H.R. 4040) to extend Medicare telehealth flexibilities enacted during the COVID-19 public health emergency through December 31, 2024. ACCC joined 375 patient and provider stakeholder groups in encouraging the Senate to adopt similar legislation to ensure a two-year extension to these telehealth policies that would allow beneficiaries to continue to utilize Medicare telehealth services from any location, including the beneficiary's home.
    Read the Letter

Recent Advocacy News Releases